These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 37221352)

  • 1. Patient Characteristics, Testing and Treatment Patterns, and Outcomes in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multinational, Real-World Study.
    Molife C; Winfree KB; Bailey H; D'yachkova Y; Forshaw C; Kim S; Taipale KL; Puri T
    Adv Ther; 2023 Jul; 40(7):3135-3168. PubMed ID: 37221352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usage of epidermal growth factor mutation testing and impact on treatment patterns in non-small cell lung cancer: An international observational study.
    Subramanian J; Leighl NB; Choi YL; Chou TY; Gregg J; Hui R; Marchetti A; Silvey M; Makin R; Gillespie-Akar L; Taylor A; Kahangire DA; Bailey T; Chau M; Navani N
    Lung Cancer; 2023 Jan; 175():47-56. PubMed ID: 36455396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Patient Characteristics, Treatment Patterns, and Mutation Testing Patterns Among US Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations.
    He J; Pericone CD; Vanderpoel J
    Adv Ther; 2022 Jul; 39(7):3347-3360. PubMed ID: 35674970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world health utility scores and toxicities to tyrosine kinase inhibitors in epidermal growth factor receptor mutated advanced non-small cell lung cancer.
    Jiang SX; Walton RN; Hueniken K; Baek J; McCartney A; Labbé C; Smith E; Chan SWS; Chen R; Brown C; Patel D; Liang M; Eng L; Sacher A; Bradbury P; Leighl NB; Shepherd FA; Xu W; Liu G; Hurry M; O'Kane GM
    Cancer Med; 2019 Dec; 8(18):7542-7555. PubMed ID: 31650705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of detecting plasma EGFR mutations with ultrasensitive liquid biopsy in outcomes of NSCLC patients treated with first- or second-generation EGFR-TKIs.
    Arrieta O; Hernandez-Martinez JM; Montes-Servín E; Heredia D; Cardona AF; Molina-Romero C; Lara-Mejía L; Diaz-Garcia D; Bahena-Gonzalez A; Mendoza-Oliva DL
    Cancer Biomark; 2021; 32(2):123-135. PubMed ID: 34057135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world outcomes, treatment patterns and T790M testing rates in non-small cell lung cancer patients treated with first-line first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors from the Slovenian cohort of the REFLECT study.
    Turnsek N; Devjak R; Edelbaher N; Osrajnik I; Unk M; Vidovic D; Jeric T; Janzic U
    Radiol Oncol; 2022 Aug; 56(3):371-379. PubMed ID: 35853681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment patterns and outcomes of patients with metastatic non-small cell lung cancer in five European countries: a real-world evidence survey.
    Bailey H; Lee A; Eccles L; Yuan Y; Burlison H; Forshaw C; Varol N
    BMC Cancer; 2023 Jun; 23(1):603. PubMed ID: 37386452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Pattern of Treatment and Clinical Outcomes of EGFR-Mutant Non-Small Cell Lung Cancer in a Single Academic Centre in Quebec.
    Agulnik JS; Kasymjanova G; Pepe C; Hurry M; Walton RN; Sakr L; Cohen V; Small D
    Curr Oncol; 2021 Dec; 28(6):5179-5191. PubMed ID: 34940073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic therapy treatment patterns in patients with advanced non-small cell lung cancer (NSCLC): PIvOTAL study.
    de Castro J; Tagliaferri P; de Lima VCC; Ng S; Thomas M; Arunachalam A; Cao X; Kothari S; Burke T; Myeong H; Grattan A; Lee DH
    Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28748556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR mutation prevalence, real-world treatment patterns, and outcomes among patients with resected, early-stage, non-small cell lung cancer in Canada.
    Sara Kuruvilla M; Liu G; Syed I; Gwadry-Sridhar F; Sheffield BS; Sachdeva R; Pencz A; Zhan L; Hueniken K; Patel D; Balaratnam K; Khan K; Grant B; Noy S; Singh K; Liu L; Rakibuz-Zaman M; Moldaver D; Kate Shanahan M; Cheema PK
    Lung Cancer; 2022 Nov; 173():58-66. PubMed ID: 36152478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Survival analysis of different kinds of tyrosine kinase inhibitors in the treatment of patients with epidermal growth factor receptor mutated non-small cell lung cancer and leptomeningeal metastasis].
    Xu HY; Chen HQ; Kong JX; Zhang Y; Liu S; Yang GJ; Wang Y
    Zhonghua Yi Xue Za Zhi; 2022 Feb; 102(6):399-405. PubMed ID: 35144338
    [No Abstract]   [Full Text] [Related]  

  • 12. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors.
    Nadler E; Pavilack M; Espirito JL; Clark J; Fernandes A
    Adv Ther; 2020 Feb; 37(2):946-954. PubMed ID: 31955357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR-mutation testing and TKI treatment patterns in locally advanced and metastatic NSCLC in Norway - A nationwide retrospective cohort study.
    Helland Å; Andersen KK; Myklebust TÅ; Johannesen TB; Aarøe J; Enerly E
    Cancer Treat Res Commun; 2022; 33():100636. PubMed ID: 36155129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Testing Practices, Treatment Patterns and Clinical Outcomes in Patients from Central Eastern Europe with EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Retrospective Chart Review Study (REFLECT).
    Janžič U; Turnšek N; Dediu M; Donev IS; Lupu R; Teodorescu G; Ciuleanu TE; Pluzanski A
    Curr Oncol; 2022 Aug; 29(8):5833-5845. PubMed ID: 36005198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
    Gelatti ACZ; Drilon A; Santini FC
    Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors.
    Chiang AC; Fernandes AW; Pavilack M; Wu JW; Laliberté F; Duh MS; Chehab N; Subramanian J
    BMC Cancer; 2020 Apr; 20(1):356. PubMed ID: 32345265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study of patient characteristics, treatment patterns,
    Winfree KB; Sheffield KM; Cui ZL; Sugihara T; Feliciano J
    Curr Med Res Opin; 2022 Jan; 38(1):91-99. PubMed ID: 34544302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR-mutation testing, treatment patterns and clinical outcomes in patients with stage IB-IIIA non-small cell lung cancer in Norway-a nationwide cohort study.
    Helland Å; Myklebust TÅ; Conte S; Frederiksen LE; Aarøe J; Enerly E
    Cancer Treat Res Commun; 2024; 38():100785. PubMed ID: 38190787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ideal sequencing in Stage IV epidermal growth factor receptor mutant Non-Small-Cell Lung Cancer.
    Walia M; Singhal MK; Kamle MS
    Indian J Cancer; 2022 Mar; 59(Supplement):S80-S89. PubMed ID: 35343193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.